[New oral anticoagulants in the treatment of venous thromboembolism].

Abstract

Rivaroxaban (with initial increased dosage) may be used as a stand-alone therapy in patients with venous thrombo-embolism. The development of new anticoagulant drugs opened several options in the management of venous thrombo-embolism. The efficacy and safety of these new oral anticoagulants in specific population as elderly and those with renal impairment deserve future research. At that time, only rivaroxaban is licensed in France, in the treatment of deep venous thrombosis.

• Authors: Laurent Bertoletti, Jean-Christophe Lega, Nathalie Moulin, Andréa Buchmuller, Patrick Mismetti, Hervé Decousus
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 42 Issue 9 Pt 1 Pg. 1232-8 (Sep 2013) ISSN: 2213-0276 [Electronic] France
• Vernacular Title: Nouveaux anticoagulants oraux dans le traitement curatif de la maladie thromboembolique veineuse.
• PMID: 23876652 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anticoagulants
• Morpholines
• Thiophenes
• Rivaroxaban

Topics

• Administration, Oral
• Anticoagulants (administration & dosage)
• Humans
• Morpholines (administration & dosage)
• Rivaroxaban
• Thiophenes (administration & dosage)
• Venous Thromboembolism (drug therapy)